Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07261371 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults
A Phase 1 study of Healthy Volunteer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT07261371 is a Phase 1 study of Healthy Volunteer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 64 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07261371, a Phase 1 study of Healthy Volunteer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of different formulations of a CGRP receptor antagonist in healthy adult participants. The study is seeking participants who are: 1. Healthy males and females 18 years of age or older 2. Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures. 3. Body Mass Index of 16-32 kilogram per meter squared (kg/m2); and a total body weight \>45 kg The study will help the team understand how difference in formulation may, or may not, affect how the medicine is absorbed, processed, and removed by the body.
Conditions Studied
Interventions
- DRUG Test formulation (Treatment A)
- DRUG Reference formulation (Treatment B)
- DRUG Test formulation (Treatment C)
- DRUG Test formulation (Treatment D)
Study Locations (1)
Connecticut
- Pfizer Clinical Research Unit - New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2026-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07261371
The ClinicalTrials.gov registry entry for NCT07261371 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (68% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 4 interventions - of which Test formulation (Treatment A) is the first listed.
NCT07261371 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07261371 about?
NCT07261371 is a clinical study titled "A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults". The purpose of this study is to assess the bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of different formulations of a CGRP receptor antagonist in healthy adult participants. The study is seeking participants who are: 1...
What is the current status of trial NCT07261371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2025-11-24. Estimated completion is 2026-05-13.
What conditions does trial NCT07261371 study?
This clinical trial studies the following conditions: Healthy Volunteer.
What interventions are being tested in trial NCT07261371?
The interventions under investigation include: Test formulation (Treatment A) (DRUG), Reference formulation (Treatment B) (DRUG), Test formulation (Treatment C) (DRUG), Test formulation (Treatment D) (DRUG).
Who is sponsoring clinical trial NCT07261371?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07261371 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.